Save One Life Add Shipments of Life-Saving Medicine to Programs

Share Article

Project SHARE now a program of Save One Life

A child with hemophilia in Guatemala receives life-saving medicine

"Supporting our beneficiaries with clotting factor when they need it the most will not only save lives but enhance the programs we already have,” said Chris Bombardier, executive director of Save One Life.

Save One Life, Inc. announced today that it is acquiring Project SHARE (Supplying Hemophilia Aid and Relief), a medical humanitarian program founded by LA Kelley Communications, Inc. Save One Life is an international nonprofit that assists people with hemophilia in developing countries.

Hemophilia is an inherited blood-clotting disorder in which the blood is unable to complete a clot due to the absence of one of 13 sequential clotting proteins. Patients require frequent injections of commercial clotting factor to stop and prevent bleeds. Project SHARE has been donating factor to developing countries for the past 20 years. To date, SHARE has donated over $140 million worth of clotting factor to 77 developing countries. The program has saved many lives, provided medicine for surgeries, allowed students to attend school and adults to work to support their families.

“The time was right to transfer this valuable humanitarian program over to an appropriate and responsible nonprofit,” explains Laureen A. Kelley, president of LA Kelley Communications and founder of Save One Life. “When I started SHARE in 2002, it wasn’t meant to be a huge program. As I traveled to developing countries to foster and train leaders for national hemophilia nonprofits, it was clear they needed blood-clotting medicine for their members. People were hurting—and dying.”

As word spread in the US about SHARE, through Kelley’s various publications, donations of blood-clotting medicine increased. In 2017, SHARE donated $45 million worth of medicine, far exceeding its budget and capacity. All donations are free of charge to recipients. Shipping costs are covered with support from corporate donors. With new leadership at Save One Life in 2019, and a mission to give direct support to families with bleeding disorders, it seemed a natural fit that SHARE joined Save One Life.

“I look forward to adding Project SHARE to the programs of Save One Life. Supporting our beneficiaries with clotting factor when they need it the most will not only save lives but enhance the programs we already have,” said Chris Bombardier, executive director of Save One Life.

Save One Life operates its child sponsorship program in 13 developing countries, but SHARE will continue to serve all patients in all countries, working with national hemophilia foundations and the treatment centers in each country. All assets of SHARE, including funds, office supplies and medicine, were transferred from LA Kelley Communications without renumeration or tax benefit.

SHARE has been supported in recent years by Baxter, Shire, Octapharma, New England BioLabs, and Novo Nordisk Inc.

Visit http://www.saveonelife.net to learn more about Save One Life and Project SHARE, or to sponsor a child with a bleeding disorder.

Visit http://www.kelleycom.com to learn more about LA Kelley Communications’s free publications for families with bleeding disorders.

About Save One Life, Inc.
Save One Life is a nonprofit that offers direct financial aid to individual children or adults with a bleeding disorder in 13 developing countries. Hemophilia is a devastating inherited blood disorder that can still cause severe pain, crippling and even death when untreated. In developing countries there is usually no budget to purchase the blood-clotting medicine needed to sustain life. Save One Life offers direct child sponsorships, college scholarships, micro-enterprise grants, camp funding and now donated blood-clotting medicine. Save One Life was founded in 2000 by Laureen A. Kelley, author and President of LA Kelley Communications, and a mother of a child with hemophilia. For more information, visit http://www.saveonelife.net or call 978-352-7652.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laureen Kelley
@LaurieKelley2
Follow >
LA Kelley Communications, Inc.
Like >
LA Kelley Communications, Inc.

Visit website